Genomic analyses indicate that the Catenin Beta 1 (CTNNB1) gene, which encodes β-catenin, exhibits gain-of-function mutations, while the axis inhibition protein1 (AXIN1) gene shows loss-of-function mutations in 15% to 35% of HCC patients [25,26,27]. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.